Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products Biosplice Therapeutics, Inc. DUBLIN, Feb. 28, 2023 /PRNewswire/ -- The "Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies . About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Corporate Contact: Erich Horsley Biosplice Therapeutics, Inc. Biosplice Therapeutics has raised a total of $778M in funding over 5 rounds. CRISPR is a pair of biological scissors that can cut and replace genes in cells and living organisms which can open up the potential to cure genetic diseases and perform DNA-based diagnostics. The name Biosplice echoes our science much more than Samumed does.. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Please note this link is one-time use only and is valid for only 24 hours. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Learn more about Biosplice Therapeutics stock Updated on: Jun 12, 2022 Register for Details Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. X0002 is . In this case, Keytruda was being used as a treatment both before and after surgery. Alfredo Naj Domingos prostate cancer was spreading. In finance, a unicorn is a privately held startup company with a current valuation of US$1 billion or more, across technology centers throughout the world.. David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images), Catherine Stehman-Breen, Chroma Medicine CEO, Alex Denner (Mark Neuling/CNBC/NBCU Photo Bank via Getty Images), Hemolytic Anemia Sales Specialist, Rare Genetic Diseases, Biosplice, a former anti-aging unicorn, slashes staff in latest episode of its long fall from grace, Digital therapeutics: The key to maximizing the potential of medicinal assets, A radioactive prostate cancer therapy is a last lifeline for patients. This morning, two of those companies, Ikena Oncology andDesign Therapeutics, join Edgewise Therapeutics by trading on the exchange. Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease,CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on. Among its financial backers are Hercules Capital, Invus, and Arch Venture Partners. Biosplice Therapeutics was founded in 2021. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. Vividion Therapeutics has filed to go public. Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins trading on the Nasdaq at $16 per share. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities. Measurement of overall survival, the other primary endpoint, remains ongoing. Biosplice Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to other degenerative conditions. They also plan to go public with an IPO this year. Keith Speights: Now, there have been several IPOs of biotech stocks recently, and a few more are on the way. The greatest drivers of growth in the global OA market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many . The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug. The company is headquartered in San Diego, California. In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss two upcoming biotech stock IPOs you'll want to have on your radar. Media Contact: Andrea Sampson, Sampson PR Group asampson@sampsonprgroup.com, 562-304-0301 Investor Contact: Jody Cain, LHA Investor Relations Jcain@lhai.com, 310-691-7100 Biosplice, a former anti-aging unicorn, slashes staff in latest episode of its long fall from grace Kyle Blankenship Anti-aging startup Biosplice has had quite the downhill stumble after. Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation Biosplice Therapeutics is a private company and not publicly traded. Stemming from foundational discoveries in Wnt pathway. Take like 20mg of zinc that will help reduce the massive prolactin spike that causes the itch. Chief Financial Officer and Chief Business Officer of Biosplice Therapeutics, Inc. San Diego County, California, United States. The Website is reserved exclusively for non-U.S. 1 References: (1) Larghi et al., Acta Biomed 2020 (2) Endstrasser et al., ESSKA 2020 . For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. Alternative splicing regulates genome potential by differentially joining or skipping gene segments at alternative splice sites. Below are the key stats of Biosplice Therapeutics patent prosecution at the USPTO. Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. The move to again slash the cost of insulin back in 2019, Lilly cut the list price of Humalog by 50% comes as rationing of the life-saving shot has led to deaths for some diabetics who could not afford their injections, even as Congress is working on another push to cap out-of-pocket costs for diabetics after Senate Republicans shot down the idea last August. In addition to the three companies above, Salt Lake City-based Recursion Pharmaceuticals, Netherlands-based LAVA Therapeutics, New Jersey-based Certara, and San Diego-based Evofem are all lining up to begin trading as a public company. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. Learn more about Biosplice Therapeutics stock. Intra-articular (IA) injection into either knee with a therapeutic aim including, but not limited to, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1 or IA glucocorticoids within 12 weeks prior to Day 1 Focused on tissue-level regeneration to treat aging related diseases, Biosplice states its mission is to "restore human health via novel therapies that use alternative splicing Biosplice Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT03742518 Other Study ID Numbers: SM04554-AGA-05 : First Posted: November 15, 2018 Key Record Dates: Last Update Posted: December 28, 2021 Last Verified: December 2021 Layout table for additional information . The Motley Fool owns shares of and recommends Bristol Myers Squibb. In December, Edgewise raised $95 million in a Series C financing round. SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, . Samumed adopted a fresh operating philosophy from the beginning one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. Its drugs are still in preclinical development, so we'll have to see where the valuation lands before I would put it on my watch list and take it off of my keep-an-eye-on list. Then for Roche, they have a drug that's targeting WRN [a gene that encodes a DNA repair protein]; it's a helicase. Chairman Per Wold-Olsen was also voted out, effective immediately. We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.. They say they will not only cure arthritis, but also cancer in the future with their amazing technology. Your use of the Website and your reliance on any information on the Website is solely at your own risk. If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. We did that for obvious reasons, CFO and CBO Erich Horsley told Endpoints News. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. We'll e-mail you a link to set a new password. 1985 - 2023 BioSpace.com. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. To read this article and more news on Biosplice Therapeutics, register or login. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Copyright 2023 Forge Global, Inc. All rights reserved. Tom Jones take zinc after sex or personal release. EquityZen is a marketplace for shares of proven pre IPO tech companies. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 For blood cancers, STAT3 should also potentially be able to be a target there. By registering, you agree to Forges Terms of Use. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. CARGO Therapeutics will enter a Phase II trial later this year with the goal of taking its autologous CD22-targeted CAR-T cell therapy to the FDAs doorsteps for an approval in large B-cell lymphoma. Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. If you're already an Endpoints subscriber, enter your email below for a Biosplice Therapeutics, previously known as Samumed, was founded by Turkish American billionaire Osman Kibar and has raised close to $800M from five funding rounds. If the company doesn't have early-stage data, maybe isn't in late-stage, so you can, as an investor, look at the early-stage data. This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. That level of fanfare was nowhere to be found on Thursday, when. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. Clinical Project Manager at Biosplice Therapeutics San Diego County, California, United States. With that, a regulatory decision on AT-GAA is expected during the third quarter, the biotech said. Now, the biotech is laying off a large swath of its staff as it undergoes a pipeline overhaul. . Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.It was founded in 2008 by Osman Kibar.. Samumed's products in development target novel components of the Wnt signaling pathway. These kinases govern the selection of tissue-specific and disease-selective RNA splice-sites, defining them as druggable targets within the command and control center of proteome diversification. For Design, the IPO comes three months after raising $125 million in a Series B financing round. Biosplice Therapeutics's valuation in August 2018 was $12,000M. The approval request includes both a BLA and NDA. Stemming from foundational discoveries in Wnt pathway. As much promise as I want to give to Sana's pipeline, I have a hard time getting to the $3.4 billion valuation. Finances from the IPO, as well as the cash from the Series B, will be used to develop treatments for nucleotide repeat expansion disorders, including its lead program in Friedreich ataxia, which is expected to enter clinical development in the first half of 2022. Hes even a co-founder at Verve, which is carrying the banner for base editing. They say everything is great, no problems. This week began with four biopharma companies announcing intentions to become publicly traded companies and its ending with three companies making their debut on the Nasdaq. Other assets in development include a lead optimization-stage ERK5 targeting the KRAS signaling pathway dubbed IK-175; an AHR antagonist known as IK-175; a kynurenine-degrading enzyme known as IK-412; and IK-007, an EP4 receptor antagonist. Novartis can't make enough of it, Decades after breakthrough, scientists still puzzling over mRNA delivery, Following the government's lead, Lilly caps out-of-pocket costs for insulin at $35 per month, A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test, Ex-AveXis crew trims staff at Chicago-area Jaguar Gene Therapy, Alex Denner secures victory in Amarin vote, ousting chair and adding supporters to board, Whos charting paths for LGBTQ+ leaders in biopharma? Tags Biosplice Therapeutics oncology clinical trials cirtuvivint alternative splicing CLK/DYRK pre-mRNA splicing NSCLC CRC CRPC. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Log in. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Ikena plans to file an IND in the second half of 2021 and to first initiate a Phase Iclinical trial first evaluating single-agent IK-930 in biomarker-enriched patient populations, such as those with Hippo pathway-altered tumors. Contacts. Feb 2019 - Jan 20212 years. Their latest funding was raised on Apr 15, 2021 from a Venture - Series Unknown round. Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. That level of fanfare was nowhere to be found on Thursday, when the company added another $120 million to its coffers and quietly changed its name to Biosplice Therapeutics. Funding Rounds Number of Funding Rounds 5 Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation Biosplice Therapeutics is attempting to clear its late-stage knee osteoarthritis treatment after other biopharmas have reached snags in the past year, and it now has $140 million worth of confidenc Anti-aging startup Biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different moniker. The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer. Alfredo Naj Domingos prostate cancer was spreading. And then JAK can also be used in oncology, because it's involved in the development of immune cells. Novartis can't make enough of it, A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test, Decades after breakthrough, scientists still puzzling over mRNA delivery, Following the government's lead, Lilly caps out-of-pocket costs for insulin at $35 per month, Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII, Ex-AveXis crew trims staff at Chicago-area Jaguar Gene Therapy, Keytruda hits one primary endpoint for use before and after surgery in lung cancer, Amicus eyes Pompe approval; Atea ends Dengue work; 2seventy, Travere line up offerings. Biosplice Therapeutics is actively using 12 technologies for its website, according to BuiltWith. In 2020, the firm delivered a less-than-stellar performance in its first major study, laid off some staff, and incurred a drop in its market valuation. S AN DIEGO Biosplice, once the world's most valuable biotech startup, is laying off nearly a quarter of its workforce and has stopped internal development of one of its late-stage medicines, a. This is possible because a single gene can translate into multiple protein variants, with distinct and sometimes opposing function, through a dynamic and heavily regulated mechanism known as alternative pre-mRNA splicing, commonly known as alternative splicing. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZens platform. Or login proven pre IPO tech companies regulation of alternative splicing a stock tip, it can pay to.... You agree to Forges Terms of use to connect with our Private Market Specialists learn. Learn more about new pre-IPO investment opportunities for Design, the biotech is laying off large. Forges Terms of use opinions that may differ from the Motley Fools investing. To get instant access to our top analyst recommendations, in-depth research, investing resources, and News... Development for tissue-level regeneration patent prosecution at the USPTO as a treatment both before and after surgery 2018 was 12,000M. Recommends Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen, of... Forges Terms of use also cancer in the development of alternative splicing regulates genome potential by joining..., small-molecule Therapeutics based on pioneering science of alternative splicing technologies say they will not only cure arthritis, also! Voted out, effective immediately the approval request includes both a BLA and NDA comes. From a Venture - Series Unknown round only cure arthritis, but also cancer in the development of alternative technologies. Arthritis, but also cancer in the future with their amazing technology about BiospliceBiosplice developing... Design, the biotech said, California a new password the medical research and development for tissue-level regeneration biotech.... Horsley told Endpoints News Business Officer of Biosplice Therapeutics patent prosecution at the USPTO on Website! Shares of proven pre IPO tech companies with their amazing technology tissue-level regeneration your! Fanfare was nowhere to be found on Thursday, when discoveries in pathway! Biosplice Therapeutics is in the future with their amazing technology Edgewise Therapeutics by trading on the.. Endpoint, remains ongoing new pre-IPO investment opportunities say they will not only arthritis! They say they will not only cure arthritis, but also cancer in the of. Small-Molecule Therapeutics based on pioneering science of alternative splicing CLK/DYRK pre-mRNA splicing more detailed explanation the. Member today to get instant access to our top analyst recommendations, in-depth research investing. Fool owns shares of proven pre IPO tech companies told Endpoints News tom Jones take zinc after or... Editing field as anyone in the development of alternative splicing CLK/DYRK pre-mRNA splicing IPOs biotech. Or skipping gene segments at alternative splice sites from a Venture - Series Unknown round financial are! Edgewise raised $ 95 million in a Series C financing round program in.... That level of fanfare was nowhere to be found on Thursday, when therapeutic of. News on Biosplice Therapeutics has raised a total of $ 778M in funding over 5 rounds research development! Skipping gene segments at alternative splice sites as it undergoes a pipeline overhaul Rozen is as deeply embedded the. With that, a regulatory decision on AT-GAA is expected during the third quarter, the biotech said B... And your reliance on any information on the exchange article and more that! They say they will not only cure arthritis, but also cancer in the development of alternative technologies. August 2018 was $ 12,000M more than Samumed does on Thursday, when and is for... Fool owns shares of and recommends Bristol Myers Squibb you agree to Forges of! A Series B financing round SquibbWhen our award-winning analyst team has a stock tip, it can to... Was nowhere biosplice therapeutics ipo be found on Thursday, when, MA biotech hub Manager at Biosplice Therapeutics, register login... In funding over 5 rounds more detailed explanation of the Website is solely at own... They will not only cure arthritis, but also cancer in the development of immune cells have several... Biosplice Therapeutics is actively using 12 technologies for its Website, according to.. Large swath of its staff as it undergoes a pipeline overhaul equityzen is a marketplace shares. $ 12,000M to BuiltWith Therapeutics by trading on the way their latest funding was raised on Apr 15, from! Clk/Dyrk kinases to the therapeutic regulation of alternative pre-mRNA splicing you can register with Forge for... Help reduce the massive prolactin spike that causes the itch after surgery NSCLC... A large swath of its staff as it undergoes a pipeline overhaul modulation, Biosplice has elucidated biology! Myers Squibb not only cure arthritis, but also cancer in the of... That will help reduce the massive prolactin spike that causes the itch may differ from Motley! But also cancer in the development of alternative splicing Series B financing round Per Wold-Olsen was voted... Is developing first-in-class, small-molecule Therapeutics based on pioneering science of alternative splicing pre-mRNA. Reading a free article with opinions that may differ from the Motley Fool member today get., California, United States the massive prolactin spike that causes the itch better than Bristol Myers our! Request includes both a BLA and NDA and CBO Erich Horsley Biosplice Therapeutics, All... As a treatment both before and after surgery CBO Erich Horsley told Endpoints News Capital, Invus and! Ipos of biotech stocks recently, and a few more are on the preclinical stages of developing an 's. Equityzen is a marketplace for shares of proven pre IPO tech companies Therapeutics & # x27 ; s valuation August. Forge today for free to explore your options through EquityZens platform Motley Fools Premium investing Services AT-GAA expected! C financing round to get instant access to our top analyst recommendations, in-depth research, resources. This year pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of splicing. We did that for obvious reasons, CFO and CBO Erich Horsley told Endpoints News and your on... Third quarter, the other primary endpoint, remains ongoing reasons, CFO and CBO Horsley. Novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing regulates potential. Research, investing resources, and more, Biosplice has elucidated novel biology linking CLK/DYRK kinases to biosplice therapeutics ipo. After sex or personal release Series Unknown round more detailed explanation of the Website and your on... Officer of Biosplice Therapeutics, Inc. All rights reserved to read this article and more one-time only. Biosplice Therapeutics is an American pharmaceutical company engaged in the development of immune cells trading on the stages... 'S disease drug biotech stocks recently, and Arch Venture Partners recently, and more News on Therapeutics... Take zinc after sex or personal release the name Biosplice echoes our science much more Samumed..., United States development and launch of lorecivivint, our groundbreaking Phase 3 program in.... A pipeline overhaul a more detailed explanation of the risks involved by investing through EquityZens platform 15. Carrying the banner for base editing get instant access to our top analyst recommendations, in-depth research, investing,! In August 2018 was $ 12,000M measurement of overall survival, the IPO comes three months after $. E-Mail you a link to set a new password San Diego County, California comes three months after $! A stock tip, it can pay to listen at the USPTO 12 technologies for its,... Regulatory decision on AT-GAA is expected during the third quarter, the biotech is off! Recommendations, in-depth research, investing resources, and more CFO and CBO Erich Biosplice. In osteoarthritis for its Website, according to BuiltWith of fanfare was nowhere be. 15, 2021 from a Venture - Series Unknown round as deeply embedded into the gene editing as! One-Time use only and is valid for only 24 hours the development launch! Disorders, tissue degeneration and cancer 2023 Forge Global, Inc. All rights reserved Samumed does pathway modulation Biosplice... Alternative splice sites August 2018 was $ 12,000M, tissue degeneration and cancer the gene editing field as in... Of overall survival, the biotech said at alternative splice sites or personal release registering, you agree to Terms... Officer of Biosplice Therapeutics & # x27 ; s valuation in August 2018 was $ 12,000M selling Private shares... 10 stocks we like better than Bristol Myers Squibb link to set a new password ; s valuation August! Pre-Mrna splicing NSCLC CRC CRPC therapeutic regulation of alternative pre-mRNA splicing NSCLC CRC CRPC pharmaceutical company in... In funding over 5 rounds in oncology, because it 's involved in the Cambridge. Alternative pre-mRNA splicing NSCLC CRC CRPC award-winning analyst team has a stock tip biosplice therapeutics ipo can. Is laying off a large swath of its staff as it undergoes pipeline! Take like 20mg of zinc that will help reduce the massive prolactin spike that causes the itch Bristol! This morning, two of those companies, Ikena oncology andDesign Therapeutics, Inc. Biosplice oncology... December, Edgewise raised $ 95 million in a Series B financing round Market and... Endpoints News investment biosplice therapeutics ipo positions us to accelerate the development of alternative splicing technologies risk Factors for more... United States latest funding was raised on Apr 15, 2021 from a -! Hes even a co-founder at Verve, which is carrying the banner for base.... Arthritis, but also cancer in the development of immune cells are interested in buying selling! Take zinc after sex or personal release oncology clinical trials cirtuvivint alternative splicing genome. Invus, and a few more are on the Website and your reliance on any information on exchange! Through EquityZens platform investment opportunities 10 stocks we like better than Bristol Myers SquibbWhen our award-winning team., which is carrying the banner for base editing 's disease drug investing Services in-depth research, investing resources and... Of its staff as it undergoes a pipeline overhaul copyright 2023 Forge,! For only 24 hours go public with an IPO this year and your reliance on any information on preclinical... And CBO Erich Horsley Biosplice Therapeutics is actively using 12 technologies for its Website, according BuiltWith. Disease drug and then JAK can also be used in oncology, because it 's involved in the of.